Division of Biomolecular and Cellular Medicine (BCM)

Biomolecular and Cellular Medicine (BCM) consists of several research groups and core facilities. Activities are translational in nature and include fundamental molecular cell biology studies, pre-clinical testing of therapy/ diagnostic agents and related activities, certified production of cell products for clinical use, phenotypical analysis of cells and tissues as well as clinical studies of patients treated with cell therapy agents.

Research themes include the development of gene therapy agents targeting e.g. neurodegenerative diseases, the use of engineered extracellular vesicles for various biomedical applications, including treatment and diagnosis of disease, the study and improvement of cytostatic drug regimens to optimize treatment efficacy, in relation to side effects, the enhancing role of cellular microenvironments in cancer cell survival as well as clinical studies on the use of CAR-T cells in cancer therapy. Core facilities provide services to customers within and outside Karolinska Institutet. BCM contributes to doctoral education and the specialist education of clinicians as well as to the programme in medicine and the biomedical analyst programme.

Research groups

Experimental Cancer medicine (ECM)

Molecular Cell Biology and Gene Therapy

Research group for Cancer evolution

Samir EL Andaloussi's research group

Mattias Carlsten's research group

Stephan Mielke's research group

Joel Nordin's research group

Caroline Palm Apergi research group

Oscar Wiklander research group

The Unit for Clinical Caring Research Focusing on Immune Diseases and Immunotherapies and on Quality and Safety in Health-care

Core facilities

Vecura

Morphological Phenotype Analysis (FENO)

Preclinical laboratory (PKL) Portal

Electron microscopy Unit

Head of Division